WCLC 2022 | Comparing progression-free survival in the ASTRIS and SANOVO trials

Qing Zhou, MD, PhD, Guangdong Lung Cancer Institute, Guangzhou, China, talks about the real world ASTRIS trial (NCT02474355), investigating osimertinib in patients with EGFR T790M-mutated non-small cell lung cancer (NSCLC). Dr Zhou discusses the results from the ASTRIS trial and compares the progression-free survival (PFS) rates to the Phase III SANOVO trial (NCT05009836). She discusses how both studies yielded similar PFS rates (11 months in ASTRIS and 10 months in SANOVO), which suggests that in both a clinical and real world setting, osimertinib is able to achieve consistent results in the EGFR T790M population. Dr Zhou hopes that in the future, other important endpoints from the ASTRIS trial can be analyzed. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.